Pharmacotherapy with ACE inhibitors and b-blockers is now recommended for most CHF patients and offers the potential to reduce morbidity and mortality associated with this disease. OBJECTIVE: The purpose of this study was to evaluate the effectiveness of b-blocker and ACE inhibitor therapy on the risk of hospitalization and total direct medical expenditures among patients with congestive heart failure enrolled in a managed care organization (MCO). METHODS: Retrospective claims data from an MCO were analyzed for the 1997-1999 period. Subjects were included if they had an ICD-9-CM code for CHF and were continuously eligible for 18 months. Subjects were categorized by whether they were receiving ACE inhibitor, ACE inhibitor + b-blocker, or neither ('notherapy'). For each group, an index date was defined based on the initiation of therapy with an ACE inhibitor or b-blocker and the initial ICD-9-CM CHF claim. The effect of each therapy on the risk of all-cause hospitalization, CHF-related hospitalization, and total direct medical costs during the subsequent 12 months following the index date was analyzed using OLS and logistic regression models. RESULTS: A total of 1903 eligible patients were included. The mean (SD) age was 69.4 ± 12.4 years, 48.8% were male, and the mean (SD) chronic disease score was 5.89 ± 3.78. ACE inhibitor therapy, but not b-blocker therapy, were associated with a significant decrease (34.7 percent, p < 0.0001) in the risk of all-cause hospitalization. Neither therapy was associated with a statistically significant effect on the risk of CHF-related hospitalization. ACE inhibitor and b-blocker therapies was associated with $2064 and $1185 lower total direct medical costs compared to the 'no-therapy' cohort (p < 0.001 for both). CONCLUSIONS: These results are similar to those of randomized trials demonstrating the benefits of ACE inhibitor. The findings for b-blocker therapies were mixed, potentially due to confounding by indication.
To contain costs associated with lipid-lowering therapy, the U.S. Department of Defense awarded a contract for the statin drugs to the manufacturers of cerivastatin and simvastatin. Hyperlipidemic patients were supposed to be converted to the preferred statins on or after October 1, 1999. OBJECTIVES: The primary goal of this study was to evaluate the clinical and economic outcomes associated with switching statin therapy of patients from a nonpreferred statin (atorvastatin, fluvastatin, lovastatin or pravastatin) to a preferred statin (cerivastatin or simvastatin).
METHODS:
The study was conducted using retrospective data from two groups of patients: those for whom statin prescription records were available (called "Pharmacy Group"); and a subset of the patients in the Pharmacy Group for whom pre-and post-conversion lipid profiles were available (called "Clinical Group"). RESULTS: For the 181,787 patients in the Pharmacy Group, the median decrease between pre-and postconversion drug cost per patient per month was $5.35. This translates into a cost avoidance of $11.7 million per year. Medication compliance of patients in the Pharmacy Group remained essentially unchanged from preconversion period (0.95) to post-conversion period (0.97). Out of the 1,552 patients in the Clinical Group for whom information on National Cholesterol Education Program goal status was available, 56.8 percent were at goal before the switch and 59.1 percent were at goal after the switch. LDL cholesterol decreased by 5.1 percent, HDL cholesterol increased by 5.8 percent, triglycerides increased by 2.1 percent, and total cholesterol decreased by 0.8 percent. CONCLUSION: The statin therapy interchange program resulted in considerable cost savings to the Department of Defense without clinically important changes in lipid profiles.
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